Skip to main content

Table 1 Patient characteristics

From: Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation

 

Total

Reactivation

p valuea

Total (%)

CMV only

EBV only

CMV and EBV

Number of patients

116

54 (47)

36

9

9

 

Sex

 M

71

30 (42)

18

8

4

0.26

 F

45

24 (53)

18

1

5

Median age (range)

49.8 (17.6–70.6)

50.7 (17.6–68.5)

55.7 (28.5–68.5)

55.8 (17.5–68.3)

56.8 (23.8–65.8)

0.43

Stemcell source

 Cord blood

1

0 (0)

0

0

0

0.30

 Peripheral blood

106

48 (45)

34

6

7

 Bone marrow

9

6 (67)

2

3

2

Donor

 Related

35

13 (37)

11

1

2

0.23

 Unrelated

81

40 (5)

25

8

7

 HLA mismatch

20

11 (55)

7

2

2

Conditioning

 NMA

106

50 (47)

36

6

8

0.47

 MA

10

4 (40)

0

2

2

 ATG

87

46 (53)

28

9

9

0.03

EBV serology (R/D)

 +/+

94

42 (45)

27

8

7

0.84

 +/−

5

3 (60)

1

0

2

 −/+

4

2 (50)

2

0

0

 −/−

11

6 (54)

5

1

0

CMV serology (R/D)

 +/+

39

28 (72)

24

0

4

<10 −4

 +/−

37

18 (49)

10

5

3

 −/+

10

2 (20)

1

0

1

 −/−

28

5 (18)

1

4

0

aGVHD

 Yes

64

29 (44)

17

5

7

0.83

 No information

19

9 (47)

8

1

0

 Relapse

14

7 (50)

2

0

0

0.78

Viral loadb

 Low (<1000 copies/ml)

NA

28 (52)

21

4

3

NA

 High (>1000 copies/ml)

NA

26 (48)

15

5

6

  1. ATG anti-thymocyte globulin; EBV Epstein-Barr virus; CMV cytomegalovirus; R/D recipient/donor; aGVHD acute graft versus host disease; NA non-applicable
  2. aComparison between reactivation and no reactivation group: unpaired t test for age, univariate analysis using Fisher’s Exact test
  3. bPatients were categorized in reactivation categories based on their peak viral load of either EBV and/or CMV DNA in plasma during 6 months post-SCT